|
NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene's myvac Platform
TOKYO, Oct 30, 2018 - (JCN Newswire) - NEC Corporation (TSE: 6701) and Transgene today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration aimed at the treatment of solid cancers. The companies will cooperate in clinically assessing the predictive capabilities of NEC's artificial intelligence (AI) and the therapeutic potential of Transgene's myvac(1) MVA-based viral vector platform in an individualized immunotherapy for the treatment of solid cancers. The experimental products from this collaboration are expected to enter clinical trials in 2019.
 | | (from left: Eric Quemeneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer, Transgene; Kaidre Bendjama, Transgene; Motoo Nishihara, Senior Vice President, Head of NEC Laboratories; Osamu Fujikawa, Senior Vice President, Business Innovation Unit, NEC Corporation) |
NEC and Transgene will co-invest in the first stage of development of an individualized immunotherapy, which includes clinical trials focusing on ovarian cancer and HPV-negative head and neck cancer.
Immunotherapy is rapidly becoming the treatment of choice to fight cancer as it activates the patient's own immune system to attack cancer cells.
NEC and Transgene have capitalized on the recent progress in AI and advances in genome sequencing to create individualized immunotherapy, which is adapted to the unique characteristics of each patient's mutational landscape as well as their predicted immune responses. The product is based on a viral vector (MVA) developed by Transgene with a proven clinical safety track record and is known for its efficient immunogenicity and anti-tumor efficacy in patients.
The viral vector will be used to target neoantigens identified using NEC's proprietary algorithm. NEC has been developing solutions in the drug discovery field for close to two decades. NEC's neoantigen prediction system(2) was developed and validated based on publicly available databases, as well as internal wet lab datasets, some of which were already used to identify clinically relevant antigens in other oncology indications.
These planned clinical trials leverage the world-leading expertise and technologies of a network of companies and research centers, including:
NEC's cutting-edge AI technology, "NEC the WISE"(3), for identifying and prioritizing patient-specific neoantigens, and Transgene's unrivaled MVA-based, viral vector technology and the myvac platform.
"The emerging personalized medicine field holds great potential for the application of NEC's core technology, and we are pleased to be working with Transgene with the goal of developing state-of-the-art personalized immunotherapies," said Motoo Nishihara, Senior Vice President, Head of NEC Laboratories.
"Engaging the body's own immune system in the fight against cancer has shown great promise and sparked unprecedented interest among oncology drug makers. This makes it imperative for NEC to become part of the immunotherapy race as soon as possible," said Osamu Fujikawa, Senior Vice President, Business Innovation Unit, NEC Corporation.
"This collaboration brings together artificial intelligence and our expertise in viral vector engineering to enable the development of a truly innovative treatment based on the myvac platform. We believe that our collaboration with NEC will allow us to provide an efficacious and robust therapy for the many patients who have solid tumors and could benefit from this cutting-edge individualized approach, and to successfully advance the development of the myvac platform to the market" said Eric Quemeneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene.
(1) myvac
myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. The myvac-derived products are designed to stimulate the patient's immune system, recognize and destroy tumors using the patient's own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities.
(2) NEC's Neoantigen Prediction System
NEC's neoantigen prediction utilizes its proprietary AI, such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets. NEC comprehensively evaluates the candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.
(3) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.
Press release:
NEC announces new AI technology brand, "NEC the WISE"
https://www.nec.com/en/press/201607/global_20160719_01.html
NEC's AI Research:
https://www.nec.com/en/global/rd/crl/ai/index.html
Contact:NEC
Seiichiro Toda
s-toda@cj.jp.nec.com
+81-3-3798-6511
Source: NEC Corporation
Sectors: Enterprise IT, BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network. |
Latest Release
MHI Thermal Systems Air-Conditioners for the Australian Market Recognized with Prestigious Awards
Oct 17, 2025 23:37 JST
| 
SEKISUI CHEMICAL, Fujitsu, and SAP Japan announce comprehensive modernization of management platform to drive data-driven approach
Oct 17, 2025 23:00 JST
| 
TransNusa to Launch Bali - Singapore Scheduled Flight on November 17
Oct 17, 2025 16:58 JST
|
MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST
| 
Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST
| 
DENSO to Exhibit at JAPAN MOBILITY SHOW 2025
Oct 16, 2025 22:53 JST
|
Fujitsu and IISc launch joint research on advanced AI technologies to accelerate new material development and resolve societal challenges
Oct 16, 2025 21:55 JST
| 
Mitsubishi Motors Wins Triple Honors at Good Design Award 2025 in Japan with the Delica Mini, Destinator and Delica Series
Oct 15, 2025 21:29 JST
|
Mitsubishi Motors at Japan Mobility Show 2025: World Premiere of Electrified Crossover SUV Concept
Oct 15, 2025 20:35 JST
|
Honda to Present World Premiere of ProZision(TM) Autonomous, at Equip Exposition 2025, Honda Battery-powered Autonomous Riding Lawn Mower
Oct 15, 2025 19:56 JST
|
Honda to Make Additional Investment in U.S.-based Helm.ai to Further Enhance Development of Next-generation AD/ADAS
Oct 15, 2025 19:25 JST
|
MHI Thermal Systems Wins 2025 GOOD DESIGN AWARD for Hyper Multi LXZ Series of Building-Use Multi-Split Air-Conditioners in Japan
Oct 15, 2025 18:50 JST
|
Mitsubishi Power Marks 60 Years in Saudi Arabia with Unveiling of First Locally Assembled JAC Gas Turbine at Dammam Assembly Facility
Oct 14, 2025 18:21 JST
| 
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Oct 14, 2025 17:54 JST
| 
Mazda Announces Exhibition at JAPAN MOBILITY SHOW 2025
Oct 14, 2025 17:38 JST
| 
Hitachi Advances Strategic Alliance with Google Cloud to Empower Frontline Workers with Field-Specific AI Agents
Oct 11, 2025 00:58 JST
|
Honda Issues Integrated Report - "Honda Report 2025"
Oct 11, 2025 00:46 JST
|
DENSO's Electrification Products Adopted for TOYOTA's New "bZ4X"
Oct 11, 2025 00:21 JST
|
Newly developed eAxle adopted for TOYOTA's new "bZ4X"
Oct 11, 2025 00:08 JST
|
MHIET and MHI-TC Complete Delivery of First "COORDY" Controller Providing Optimized Control of Multiple Power Sources
Oct 10, 2025 23:47 JST
|
More Latest Release >>
|